公告还称，本次交易尚需中国证监会予以注册以及相关法律法规所要求的其他可能涉及的必要批准、核 准、备案或许可(如需)后方可正式实施，能否实施尚存在不确定性。 中国船舶集团旗下两大市值千亿元级上市公司重组整合迎来重要进展。7月4日，中国船舶工业股份有限 公司(以下简称"中国船舶")发布公告称，公司吸收合并中国船舶重工股份有限公司(以下简称"中国重工 （601989）")事项获上海证券交易所(以下简称"上交所")审核通过。 此次重组完成后，存续公司中国船舶将成为全球最大造船上市公司，资产规模、营业收入规模、手持订 单数均领跑全球。截至7月4日收盘，中国船舶市值达到1467亿元，中国重工市值为1056亿元。 上交所审议通过 7月4日，中国船舶发布公告称，中国船舶拟向中国重工全体换股股东发行A股股票的方式换股吸收合并 中国重工。上交所并购重组审核委员会7月4日召开2025年第8次并购重组审核委员会审议会议，对公司 本次交易的申请进行了审议。审议结果为，本次交易符合重组条件和信息披露要求。 此前，2024年9月2日晚，中国船舶发布关于筹划重大资产重组停牌公告。公告称，为进一步聚焦国家重 大战略和兴装强军主责主业、加快船舶 ...

Core Viewpoint - Chuangjian Medical (NQ873474) reported a significant decline in net profit for the fiscal year 2024, with a year-on-year decrease of 50.84% [1] Financial Performance - The company achieved operating revenue of 288.15 million yuan, a year-on-year increase of 1.82% [2] - The net profit attributable to shareholders was 33.82 million yuan, down 50.84% from the previous year [2] - The net profit after deducting non-recurring gains and losses was 26.77 million yuan, a decrease of 58.04% [2] - Basic earnings per share were 0.81 yuan, down 53.98% compared to 1.76 yuan in the previous year [2] - The weighted average return on equity was 6.31%, compared to 23.55% in the previous year [2] - The gross profit margin for the period was 73.94%, down from 78.17% year-on-year [2] Business Segments - Revenue from terminal products reached 182 million yuan, reflecting a year-on-year growth of 29.95%, although the gross margin decreased to 70.81% [3] - The revenue from the restructured collagen raw material business was 104 million yuan, down 26.23% year-on-year, with a gross margin of 79.24%, a decrease of 2.09% [3] - The decline in performance was attributed to strategic adjustments in product structure and a reduction in sales volume for certain products [3] Employee Statistics - The total number of employees increased to 503, up 18.35% from 425 at the end of the previous year [4]

创业板指盘初涨幅扩大至1%，上证指数现涨0.15%；大医药概念集体反弹，CRO、创新药、单抗、重组 蛋白等概念走强；全市约3800股上涨，1300股下跌，主力资金净流出超20亿元。 ...

Market Overview - The A-share market opened with mixed performance, with the Shanghai Composite Index up 0.04% at 3474.63 points, while the Shenzhen Component Index and the ChiNext Index fell by 0.04% and 0.03% respectively [2][3] - The Hong Kong market saw the Hang Seng Index rise by 0.17% and the Hang Seng Tech Index increase by 0.28%, with notable gains in companies like Far East Horizon and Kingstone Pharmaceuticals [4] Sector Performance - Advanced packaging, semiconductor, and power sectors showed strength, while tax refund stores, recombinant protein, and CPO concepts opened lower [1] - The storage chip sector led gains, with companies like Jingzhida rising over 7% following news of Changxin Memory's listing guidance [1] - Shipping and port concepts also performed well, with Ningbo Ocean and Ningbo Shipping both rising over 3% amid news of Houthi attacks on Red Sea merchant ships [1] Monetary Policy - The central bank conducted a 690 billion yuan reverse repurchase operation with a rate of 1.40%, while 1310 billion yuan of reverse repos are set to mature today [5] Currency Exchange - The RMB against the USD was adjusted down by 28 basis points to a midpoint of 7.1534, with the onshore closing price at 7.1747 [6]

Core Viewpoint - The life sciences upstream sector is showing signs of recovery with a year-on-year growth rate of 9.5% in Q1 2025, driven by stable investment and financing, cost reduction, and domestic substitution trends [1] Group 1: Industry Trends - The life sciences upstream sector, which includes instruments, consumables, raw materials, and services, is characterized by specialization, high barriers, and cyclicality [1] - The sector experienced a downturn after rapid growth during the pandemic, but leading companies are expanding and increasing their international presence [1] - Major companies are expected to see a revenue growth rate of 10.75% in 2024, with a significant recovery in Q1 2025 compared to 2023 [1] Group 2: Market Opportunities - The global and Chinese biopharmaceutical markets are thriving, with projections indicating that the Chinese antibody drug market will reach 510.8 billion RMB by 2030 and the CGT market will reach 2.59 billion USD by 2025, providing substantial market growth for the upstream sector [2] - The domestic innovative drug market is heating up, which is likely to accelerate demand for life sciences upstream products [2] Group 3: Domestic Substitution and Innovation - The increasing tariff barriers are enhancing domestic self-sufficiency, allowing local companies to enter major supply chains as cost reduction and supply chain security become more critical [2] - Long-term success in domestic substitution will depend on technological innovation, with local firms increasing R&D investments and moving from low-end to mid-to-high-end products [2] Group 4: Mergers and Acquisitions - Historical analysis of global life sciences giants shows that mergers and acquisitions have been key to their growth, allowing them to focus on core businesses and expand capabilities [3] - Recent favorable policies for mergers and acquisitions, along with the cash-rich status of many life sciences companies, are expected to accelerate consolidation in the sector [3] - Domestic companies are likely to replicate the growth paths of overseas giants through mergers and acquisitions, increasing industry concentration and extending their reach into downstream markets [3]

Core Viewpoint - Shaoyang Hydraulic (301079) has announced a major asset restructuring plan, revealing significant changes in shareholder composition and stock price movements prior to the announcement [1][19]. Shareholder Changes - A new investor named "Li Yuanfang" has emerged as the fifth largest shareholder, holding 724,200 shares, which is 0.66% of the total share capital. This investor was not listed in the previous quarterly report [1][4]. - Another shareholder, "Cao Kangseng," is now the seventh largest shareholder with 537,750 shares, representing 0.49% of the total share capital [3][5]. - Notably, foreign entities Morgan Stanley & Co. International PLC and UBS AG were absent from the latest shareholder list [3][5]. Stock Price Movements - On the trading day before the announcement, Shaoyang Hydraulic's stock price rose by 11.93%, closing at 31.90 CNY per share, compared to 28.50 CNY per share 21 trading days prior [9][19]. - The stock's performance was contrasted with the broader market, where the ChiNext Index fell by 1.74% and the CITIC Machinery Index dropped by 2.62% during the same period [9]. Financial Performance - Shaoyang Hydraulic reported a revenue of 276 million CNY in 2023, a decrease of 8.32% year-on-year, and a net profit of 6.58 million CNY, down 86.88% [16]. - For 2024, the company expects a revenue increase to 351 million CNY, a rise of 27.33%, but a slight decline in net profit to 6.40 million CNY, down 2.76% [16][18]. - The company ranks 142nd out of 213 in total market capitalization within its industry, indicating a relatively weak financial position compared to peers [18]. Asset Acquisition - The target company for the acquisition, Chongqing Xincheng Hangrui Technology Co., Ltd., reported revenues of 353.23 million CNY and 346.65 million CNY for 2023 and 2024, respectively, with net profits of 43.51 million CNY and 30.23 million CNY [14][15]. - The acquisition aims to create synergies and enhance the company's supply chain [14]. Confidentiality Measures - Shaoyang Hydraulic has stated that it has implemented necessary measures to prevent information leakage regarding the asset restructuring and has adhered to confidentiality obligations [10][19].

Group 1 - The year 2025 marks the conclusion of the deepening reform actions for state-owned enterprises, with multiple regions intensifying policies to support mergers and acquisitions of state-owned enterprises [1] - Nanjing Tourism Group is set to integrate with Nanjing Cultural Investment Holding Group and Nanjing Sports Industry Group to create a comprehensive development and operation platform for cultural tourism and sports in Nanjing [1] - The Nanjing municipal government has issued measures to promote high-quality development of mergers and acquisitions, focusing on optimizing equity structure and enhancing operational efficiency [1] Group 2 - Nanjing Tourism Group is advancing a capital injection plan into Nanjing Commercial Tourism Co., which includes acquiring 100% equity of Nanjing Huangpu Grand Hotel through a combination of share issuance and cash payment [2] - The strategic restructuring of Nanjing Commercial Tourism's controlling shareholder aligns with national directives for deepening state-owned enterprise reforms, aiming to enhance the integration of tourism, culture, and sports sectors [2] - The restructuring is expected to significantly influence Nanjing Commercial Tourism's future strategic positioning and business expansion, allowing for the exploration of synergies across industries [2] Group 3 - In addition to the cultural tourism sector, there have been frequent mergers and acquisitions in energy, high-end equipment, and electronic information sectors this year [3] - Inner Mongolia Electric Power Investment Co. announced plans to restructure assets by acquiring 100% equity of Baiyin Hua Coal Power Co. to optimize resource allocation in the region [3] - China Shipbuilding Industry Co. is merging with China Shipbuilding Heavy Industry Co., with the merger approved by the Shanghai Stock Exchange's review committee [3] Group 4 - In the electronic information sector, Guotou Zhonglu Juice Co. plans to acquire 100% equity of China Electronic Engineering Design Institute through share issuance, expanding its business scope beyond juice production [4] - The year 2025 is critical for the deepening reform of state-owned enterprises, emphasizing the need for clear restructuring objectives and effective coordination mechanisms [4]

7月7日晚间，中核科技公告称，公司决定终止发行股份购买西安中核核仪器股份有限公司（以下简称中 核西仪）98.87%股份并募集配套资金的交易事项。 公告显示，中核科技筹划本次交易预计构成重大资产重组与关联交易，并且符合其所处行业通过并购重 组方式强化竞争力的发展趋势。 同时，上述交易是中国核工业集团有限公司（以下简称中核集团）将优质资产注入其控股上市公司的重 要举措。据悉，中核科技与中核西仪均由中核集团控制。 官网显示，中核集团是中央直接管理的特大型国有重要骨干企业，也是国家核科技工业的主体，资产规 模约为1.4万亿元。 市场环境与中核西仪有变 中核科技公告称，公司决定终止本次交易事项，主要是当前市场环境及中核西仪的实际情况，相比于本 次交易的筹划初期发生了一定的变化。 交易预案显示，截至2024年9月30日，中核科技的总资产为26.63亿元，净资产为14.91亿元。 2022年、2023年及2024年前三季度，中核科技的营业收入分别为11.49亿元、13.24亿元、6.63亿元，净 利润分别为1.77亿元、1.64亿元、8159.76万元。 | | | | 单位:万元 | | --- | --- | --- ...

Market Performance - On July 7, 2025, the Shanghai Composite Index rose by 0.02%, while the Shenzhen Component Index fell by 0.70% and the ChiNext Index decreased by 1.21%[3] - The total market turnover was 1,208.497 billion yuan, a decrease of 219.868 billion yuan compared to the previous trading day[3] - Out of 3,286 stocks, 2,010 declined while 1,276 advanced[3] Sector Performance - The top-performing sectors included Comprehensive Finance (up 2.21%), Real Estate (up 1.70%), and Electric Power & Utilities (up 1.50%) while the laggards were Pharmaceuticals (down 0.94%), Communications (down 0.80%), and Home Appliances (down 0.73%)[3][21] - The market style ranking was Stable > Financial > Cyclical > Neutral > Growth > Consumer[21] Capital Flow - On July 7, 2025, the net outflow of main funds was 18.268 billion yuan, with large orders seeing a net outflow of 11.283 billion yuan and small orders experiencing a net inflow of 19.967 billion yuan[4][26] - Southbound capital saw a net inflow of 12.067 billion HKD, with the Shanghai-Hong Kong Stock Connect contributing 5.791 billion HKD and the Shenzhen-Hong Kong Stock Connect contributing 6.276 billion HKD[5][28] ETF Trading - Major ETFs such as the Huaxia SSE 50 ETF and the Huatai-PB CSI 300 ETF saw significant decreases in trading volume, with changes of -7.82 billion yuan and -26.26 billion yuan respectively[4][31] - The total trading volume for ETFs on July 7 was 12.08497 billion yuan, reflecting a decrease from the previous trading day[31] Global Market Overview - On July 7, 2025, major Asia-Pacific indices showed mixed results, with the Hang Seng Index down 0.12% and the Nikkei 225 down 0.56%[5][34] - European indices also experienced declines, with the DAX down 0.61% and the CAC40 down 0.75% on July 4, 2025[5][34]

【 导读 】中核科技终止 筹划重大资产重组，系 市场环境及标的公司 有变 中国基金报记者 闻言 7月7日晚间，中核科技公告称，公司决定终止发行股份购买西安中核核仪器股份有限公司 （以下简称中核西仪）98.87%股份并募集配套资金的交易事项。 公告显示，中核科技筹划本次交易预计构成重大资产重组与关联交易，并且符合其所处行业 通过并购重组方式强化竞争力的发展趋势。 同时，上述交易是中国核工业集团有限公司（以下简称中核集团）将优质资产注入其控股上 市公司的重要举措。据悉，中核科技与中核西仪均由中核集团控制。 官网显示，中核集团是中央直接管理的特大型国有重要骨干企业，也是国家核科技工业的主 体，资产规模约为1.4万亿元。 市场环境与中核西仪有变 中核科技公告称，公司决定终止本次交易事项，主要是当前市场环境及中核西仪的实际情 况，相比 于 本次交易 的 筹划初期发生了 一定的变化。 交易预案显示，截至2024年9月30日，中核科技的总资产为26.63亿元，净资产为14.91亿 元。 2022年、2023年及2024年前三季度，中核科技的营业收入分别为11.49亿元、13.24亿元、 6.63亿元，净利润分别为1.77亿 ...